Inhibikase Therapeutics, Inc. (IKT) Stock Price & Analysis
Inhibikase Therapeutics, Inc. (IKT) closed at USD 1.83 on Thursday, October 15, 2026, up 1.67% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.8; the Oct 15, 2026 session ranged USD 1.8–1.87 on volume of 400,740 shares. Market capitalization is $255.35M, with a 52-week range of USD 1.33–2.61 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:20 UTC.
Also available as compact Markdown for AI agents: nexqual.com/IKT.md
Key facts (IKT)
- Analysts: Buy (mean 2.00 on a 1–5 scale) (10 analysts), mean target USD 5.55 (range 1.5–8).
- Total return with dividends: 1Y +21.2% vs S&P 500 +18.1%; 5Y -84.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-13, EPS estimate USD -0.13, revenue estimate $0K.
Analysts (IKT)
Consensus Buy (mean 2.00 on a 1–5 scale), 10 analysts; mean target USD 5.55 (low 1.5, high 8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | Chardan Capital | Initiated | Neutral | $1.5 |
Total return (dividends reinvested) (IKT)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +21.2% | -84.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +21.3% | -30.8% |
| Volatility (annualized) | 61.5% | 88.5% |
| Max drawdown | -30.2% (Sep 2026→Oct 2026) | -93.6% (Nov 2021→Oct 2023) |
Key Statistics (as of October 16, 2026 at 05:20 UTC)
| Price | USD 1.83 |
|---|---|
| Change | ▲ 1.67% (up) |
| Previous Close | USD 1.8 |
| Open | USD 1.8 |
| Day Range | USD 1.8 – 1.87 |
| 52-Week Range | USD 1.33 – 2.61 |
| Volume | 400,740 shares |
| Market Cap | $255.35M |
| Exchange | NCM |
Technical Analysis (IKT)
Nexqual's technical model rates IKT "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:20 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 33.97 (neutral) |
| vs SMA50 | Below (USD 2.25) |
| MACD | -0.12 (negative) |
Analyst Ratings (IKT)
Wall Street analysts rate IKT "Buy" based on 10 analysts, with a mean price target of USD 5.55 (range USD 1.5–8), per Nexqual as of October 16, 2026 at 05:20 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 5.55 |
| High Target | USD 8 |
| Low Target | USD 1.5 |
| Buy / Hold / Sell | 9 / 1 / 0 |
Earnings (IKT)
| Next Earnings Date | 2026-11-13 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.09 ▼ miss |
| 2025-12-31 | USD -0.09 vs est -0.12 ▲ beat |
| 2025-09-30 | USD -0.13 vs est -0.13 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financials & Fundamentals (IKT)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -51.96% |
| Current Ratio | 15.82 |
| Total Cash | $159.02M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Financial Health Score (IKT)
Nexqual rates Inhibikase Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:20 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $159M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$43M (TTM) |
| Efficiency | Critical — ROE -52%, ROA -32.8% |
Ownership (IKT)
| Insider Ownership | +6.09% |
|---|---|
| Institutional Ownership | +89.72% |
| Shares Outstanding | 139.54M |
| Float | 107.13M |
| Short % of Float | +21.68% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Leadership (IKT)
Inhibikase Therapeutics, Inc. is led by Mark T. Iwicki (age 59), CEO & Director, per Nexqual as of October 16, 2026 at 05:20 UTC.
| CEO & Director | Mark T. Iwicki (age 59) |
|---|---|
| President, Head of Research & Development and Chief Medical Officer | Christopher H. Cabell FACC (age 56) |
| Chief Financial Officer | David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B. (age 55) |
| Chief Scientific Officer | John Adams |
Major Backers & Investors (IKT)
Notable institutional backers of Inhibikase Therapeutics, Inc. include Sands Capital Alternatives, LLC, Soleus Capital Management, L.P., Trails Edge Capital Partners, LP, according to Nexqual as of October 16, 2026 at 05:20 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sands Capital Alternatives, LLC | 9.33% |
| Soleus Capital Management, L.P. | 7.79% |
| Trails Edge Capital Partners, LP | 6.49% |
| Fairmount Funds Management LLC | 6.18% |
| Adar1 Capital Management, LLC | 5.29% |
| Blackstone Inc | 4.26% |
| Siren, L.L.C. | 4.19% |
| Commodore Capital Lp | 3.87% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 8.76% |
| Vanguard Group | 7.39% |
Source: Nexqual, October 16, 2026 at 05:20 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:20 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt